This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / CASI Pharmaceuticals Delisted from Nasdaq
Business Delisting

CASI Pharmaceuticals Delisted from Nasdaq

Analysis based on 7 articles · First reported Feb 25, 2026 · Last updated Feb 25, 2026

Sentiment
-20
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The delisting of CASI Pharmaceuticals from Nasdaq is a negative event for its shareholders, as it moves to a less liquid and prestigious market. While CASI Pharmaceuticals states no significant operational impact, the move to OTC Markets Group Inc. may reduce investor confidence and trading volume.

Biotechnology Pharmaceuticals
Event Summary

CASI Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it received a determination letter from The Nasdaq Stock Market's Hearings Panel to delist its securities. The delisting is effective February 26, 2026, due to the company's failure to satisfy continued listing conditions. CASI Pharmaceuticals does not intend to appeal the decision and expects its ordinary shares to be quoted on the OTC Markets Group Inc. following the delisting. The company stated that the delisting will not significantly impact its operations.

Key Actions
100 Nasdaq Delisted securities CASI Pharmaceuticals
90 CASI Pharmaceuticals Failed to satisfy listing conditions Nasdaq
70 CASI Pharmaceuticals Will be quoted on over-the-counter market OTC Markets Group
Entities Involved
stock
CASI Pharmaceuticals
CASI Pharmaceuticals will be delisted from Nasdaq due to failure to satisfy continued listing conditions. Its securities will be suspended from trading on February 26, 2026, and will subsequently be quoted on the OTC Markets Group Inc. This delisting is expected to have no significant impact on the company's operations.
Importance 100 Sentiment -70
exch
Nasdaq
Nasdaq has determined to delist CASI Pharmaceuticals' securities due to the company's failure to meet continued listing conditions. This action reflects Nasdaq's role in maintaining listing standards.
Importance 80 Sentiment 0
exch
OTC Markets Group
OTC Markets Group Inc. is expected to quote CASI Pharmaceuticals' ordinary shares following its delisting from Nasdaq, potentially allowing a trading market to continue for the company's shares.
Importance 40 Sentiment 0
govactor
United States===United States Securities and Exchange Commission
The United States===United States Securities and Exchange Commission is mentioned in the context of CASI Pharmaceuticals' periodic reports and filings, indicating its regulatory oversight.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.